AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis

NNDSS - TABLE 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 527354: 16,20-Dimethyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 17,21-dimethyldotriacontanenitrile. Molecular Formula: C34H67N. Molecular Weight: 489.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
How should an infected perinephric haematoma be drained in a tetraplegic patient with baclofen pump implanted in the abdominal wall? – A case report

Background
          We present a case to illustrate controversies in percutaneous drainage of infected, perinephric haematoma in a tetraplegic patient, who had implantation of baclofen pump in anterior abdominal wall on the same side as perinephric haematoma.
        
        
          Case presentation
          A 56-year-old male with C-4 tetraplegia had undergone implantation of programmable pump in the anterior abdominal wall for intrathecal infusion of baclofen to control spasticity. He developed perinephric haematoma while he was taking warfarin as prophylactic for deep vein thrombosis. Perinephric haematoma became infected with a resistant strain of Pseudomonas aeruginosa, and required percutaneous drainage. Positioning this patient on his abdomen without anaesthesia, for insertion of a catheter from behind, was not a realistic option. Administration of general anaesthesia in this patient in the radiology department would have been hazardous.
        
        
          Results and Conclusion
          Percutaneous drainage was carried out by anterior approach under propofol sedation. The site of entry of percutaneous catheter was close to cephalic end of baclofen pump. By carrying out drainage from anterior approach, and by keeping this catheter for ten weeks, we took a risk of causing infection of the baclofen pump site, and baclofen pump with a resistant strain of Pseudomonas aeruginosa. The alternative method would have been to anaesthetise the patient and position him prone for percutaneous drainage of perinephric collection from behind. This would have ensured that the drainage track was far away from the baclofen pump with minimal risk of infection of baclofen pump, but at the cost of incurring respiratory complications in a tetraplegic subject.
NNDSS - Table II. Babesiosis to Coccidioidomycosis

NNDSS - Table II. Babesiosis to Coccidioidomycosis - 2014.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Case counts for reporting year 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
Behavioral Health Barometer: Utah, 2014

This is a behavioral health report for the state of Utah. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Mannosylerythritol lipid, a yeast extracellular glycolipid, shows high binding affinity towards human immunoglobulin G

Background
          There have been many attempts to develop new materials with stability and high affinity towards immunoglobulins. Some of glycolipids such as gangliosides exhibit a high affinity toward immunoglobulins. However, it is considerably difficult to develop these glycolipids into the practical separation ligand due to their limited amounts. We thus focused our attention on the feasible use of "mannosylerythritol lipid A", a yeast glycolipid biosurfactant, as an alternative ligand for immunoglobulins, and undertook the investigation on the binding between mannosylerythritol lipid A (MEL-A) and human immunoglobulin G (HIgG).
        
        
          Results
          In ELISA assay, MEL-A showed nearly the same binding affinity towards HIgG as that of bovine ganglioside GM1. Fab of human IgG was considered to play a more important role than Fc in the binding of HIgG by MEL-A. The bound amount of HIgG increased depending on the attached amount of MEL-A onto poly (2-hydroxyethyl methacrylate) (polyHEMA) beads, whereas the amount of human serum albumin slightly decreased. Binding-amount and -selectivity of HIgG towards MEL-A were influenced by salt species, salt concentration and pH in the buffer solution. The composite of MEL-A and polyHEMA, exhibited a significant binding constant of 1.43 × 106 (M-1) for HIgG, which is approximately 4-fold greater than that of protein A reported.
        
        
          Conclusions
          MEL-A shows high binding-affinity towards HIgG, and this is considered to be due to "multivalent effect" based on the binding molar ratio. This is the first report on the binding of a natural human antibody towards a yeast glycolipid.
Compound 525879: N,N-Dimethyl-N'-(3-methylphenyl)-pivalamidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2,2-tetramethyl-N'-(3-methylphenyl)propanimidamide. Molecular Formula: C14H22N2. Molecular Weight: 218.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 323613: Voacangine 11-(3,4-dimethoxybenzyl)

Chemical compound data from PubChem database. IUPAC Name: methyl (15S,17R)-8-[(3,4-dimethoxyphenyl)methyl]-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-1-carboxylate. Molecular Formula: C31H38N2O5. Molecular Weight: 518.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]

Background
          Fermented milk products have been shown to affect serum cholesterol concentrations in humans. Kefir, a fermented milk product, has been traditionally consumed for its potential health benefits but has to date not been studied for its hypocholesterolemic properties.
        
        
          Methods
          Thirteen healthy mildly hypercholesterolemic male subjects consumed a dairy supplement in randomized crossover trial for 2 periods of 4 wk each. Subjects were blinded to the dairy supplement consumed. Blood samples were collected at baseline and after 4 wk of supplementation for measurement of plasma total, low-density lipoprotein, and high-density lipoprotein cholesterol and triglyceride concentrations, as well as fatty acid profile and cholesterol synthesis rate. Fecal samples were collected at baseline and after 2 and 4 wk of supplementation for determination of fecal short chain fatty acid level and bacterial content.
        
        
          Results
          Kefir had no effect on total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglyceride concentrations nor on cholesterol fractional synthesis rates after 4 wk of supplementation. No significant change on plasma fatty acid levels was observed with diet. However, both kefir and milk increased (p < 0.05) fecal isobutyric, isovaleric and propionic acids as well as the total amount of fecal short chain fatty acids. Kefir supplementation resulted in increased fecal bacterial content in the majority of the subjects.
        
        
          Conclusions
          Since kefir consumption did not result in lowered plasma lipid concentrations, the results of this study do not support consumption of kefir as a cholesterol-lowering agent.
Compound 527381: 20-Methyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 21-methyldotriacontanenitrile. Molecular Formula: C33H65N. Molecular Weight: 475.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AH Provisional COVID-19 Deaths by HHS Region, Race, and Age Group, 2020-2021

Provisional deaths involving coronavirus disease 2019 (COVID-19) reported to NCHS by time-period (week, month, year), HHS region, race and Hispanic origin, and age group (0-24, 25-64, 65+ years) for 2020-2021.

United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins

An explanation for the higher incidence of cardiovascular disease and heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) with doxazosin and the Vasodilator Heart Failure Trial (V-HeFT) with prazosin might be decreased expression of heat shock proteins. Heat shock proteins help to protect cells from ischemic injury by decreasing oxidation, suppressing cytokine action, refolding damaged proteins, and decreasing apoptosis. I hypothesize that α-adrenergic blockade decreases heat shock protein levels, thus making the heart and vascular system vulnerable to injury from pathologic processes such as ischemia, hypertension, oxidation or inflammation. Similarly, poor cardiovascular outcomes with calcium-channel blockers might be due to decreased expression of heat shock proteins.
Patent AT-E401401-T1: [Translated] IL-2R-ASSOCIATED POLYPEPTIDE AND DNA MOLECULES ENCODING THEREOF

The present invention relates to a polypeptide, p43, which is associated with the interleukin-2 receptor (IL-2R). It binds specifically to the beta and gamma subunits of IL-2R and is further capable of binding NAD+. The invention is further related to nucleic acid molecules coding for p43 and to antibodies specifically binding to p43.
The use of alternative therapies in the Saskatchewan stroke rehabilitation population

Background
          Many patients use alternative therapies. The purpose of this study was to determine the percentage of stroke rehabilitation patients in Saskatchewan using alternative therapies, whether patients found these therapies effective in alleviating stroke-related symptoms, how often those patients who used alternative therapies discuss this fact with their primary care doctor and the main reason why patients might not do so.
        
        
          Methods
          Telephone questionnaire surveys were conducted with 117 patients who had suffered a stroke and undergone inpatient or outpatient rehabilitation at Saskatoon City Hospital.
        
        
          Results
          The study revealed that 26.5% of 117 stroke rehabilitation patients visited alternative practitioners at least once or used some form of unconventional therapy. Only 16.1% of patients found that alternative therapy made them feel much better. Of those who used alternative therapy, 61.3% did not discuss this fact with their primary physician. Many of the respondents (47.3%) who did not inform their physician stated that they did not see the necessity of talking about these treatments and 21.1% did not discuss the issue with their physician because they felt that he or she might disapprove of alternative therapies.
        
        
          Conclusion
          A relatively small percentage of stroke patients found alternative therapies beneficial. Doctors should be aware that a significant number of patients will try alternative treatment without discussion with their primary care physician or specialist. The current study suggests that after completing routine questioning, doctors should also ask their patients about their use of alternative therapies and, when appropriate, review issues of safety and efficacy.
Compound 527109: 1-Pentanamine, 1-methyl, N-propyl

Chemical compound data from PubChem database. IUPAC Name: N-methyl-N-propylpentan-1-amine. Molecular Formula: C9H21N. Molecular Weight: 143.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400395-T1: [Translated] SOLDER PASTES

A solder paste comprising a powder of a Zn-containing Sn-based, lead-free solder mixed with an activator-containing rosin-based flux to which 0.5 - 10.0 wt% of isocyanuric acid or a haloalkyl ester thereof is added can prevent the formation of solder balls and voids during reflow soldering and exhibit good solderability. A solder paste comprising a powder of an Ag- or Zn-containing Sn-based, lead-free solder mixed with an activator-containing rosin-based flux to which 0.01 - 10.0 wt% of a salicylamide compound also does not exhibit a change in viscosity and exhibits good solderability.
Compound 527321: methyl 2-[5-(4-chlorophenyl)-2-(4-methoxyphenyl)-2H-imidazol-4-yl]acetate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[5-(4-chlorophenyl)-2-(4-methoxyphenyl)-2H-imidazol-4-yl]acetate. Molecular Formula: C19H17ClN2O3. Molecular Weight: 356.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529177: 5-Amino-1-pentanol, N-(tert-butyldimethylsilyl)-, tert-butyldimethylsilyl ether

Chemical compound data from PubChem database. IUPAC Name: N-[tert-butyl(dimethyl)silyl]-5-[tert-butyl(dimethyl)silyl]oxypentan-1-amine. Molecular Formula: C17H41NOSi2. Molecular Weight: 331.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401633-T1: [Translated] SLOT MACHINE

The machine comprises a door provided on a front face of a cabinet with a bill insertion slot provided in the door. A bill guide plate (52A) provided on the door, extending outwards from a lower end of a slot, guides the bill into the slot. The guide plate comprising several rectilinear slit openings (521), parallel to each other separates foreign matter from the bill and drops the foreign matter.
Alcohol and Drug Combinations Are More Likely to Have a Serious Outcome Than Alcohol Alone in Emergency Department Visits Involving Underage Drinking

This Drug Abuse Warning Network (DAWN) spotlight looks at the outcomes of emergency department visits that involve underage drinking in 2011. The report compares the outcome of emergency department vists by patients ages 12-20 that involved alcohol only, to visits where other drug(s) were taken along with alcohol.
2014 CMHS Uniform Reporting System (URS) Table for Alabama

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Alabama. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527316: Methyl 2-[5-methoxy-1-(4-methoxybenzoyl)-2-methylindol-3-yl]acetate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[5-methoxy-1-(4-methoxybenzoyl)-2-methylindol-3-yl]acetate. Molecular Formula: C21H21NO5. Molecular Weight: 367.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527226: 1-((1S,2R,3R)-2-(3-Isopropylfuran-2-yl)-3-methylcyclopentyl)ethanone

Chemical compound data from PubChem database. IUPAC Name: 1-[3-methyl-2-(3-propan-2-ylfuran-2-yl)cyclopentyl]ethanone. Molecular Formula: C15H22O2. Molecular Weight: 234.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Blog | COVID-19 TOPx Tech Sprint Begins with Design-a-thon Teams — Join us!

This blog post was posted by Kevin Duvall on January 19, 2021. It was written by Kristen Honey, Chief Data Scientist and Senior Advisor to the Assistant Secretary for Health (ASH), U.S. Department of Health and Human Services (HHS); Alex Wilson, IT Specialist, Office of the Assistant Secretary for Health (OASH), HHS; and Sara Brenner, Diagnostic Data Lead, Data Strategy and Execution Workgroup, HHS; Chief Medical Officer for In Vitro Diagnostics, Associate Director for Medical Affairs, CDRH, U.S. Food & Drug Administration (FDA).
Compound 530244: delta-9 Thc trifluoroacetate

Chemical compound data from PubChem database. IUPAC Name: (6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl) 2,2,2-trifluoroacetate. Molecular Formula: C23H29F3O3. Molecular Weight: 410.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401539-T1: [Translated] CRYO DEVICE AND ASSOCIATED OPERATING METHOD

The invention relates to a cryoapparatus for freezing and/or thawing a sample (1), especially in the cryopreservation of a biological sample (1), with a coolable cooling space (3) and with a sample container (10) arranged in the cooling space (3) for temporarily receiving the sample (1) when freezing or thawing the sample (1). It is suggested that the sample container (10) can be tempered separately from the cooling space. Furthermore, the invention includes an associated operating method.
Compound 530117: 1-(Trimethylsilyl)-5-[(trimethylsilyl)oxy]-3-(2-[(trimethylsilyl)oxy]ethyl)-1H-indole

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[5-trimethylsilyloxy-3-(2-trimethylsilyloxyethyl)indol-1-yl]silane. Molecular Formula: C19H35NO2Si3. Molecular Weight: 393.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.